

ctitioner's Docket No. <u>MPI98-052P1RDV10DV1M</u>



**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Susan L. Acton		
Application No.:	10/786,501	Group No.:	1653
Filed:	February 25, 2004	Examiner:	MONSHIPOURI, MARYAM
For:	NOVEL PROTEIN KINASE MOLECULES AND USES THEREFOR		

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 **Confirmation No. 3988** 

## **TRANSMITTAL**

- 1. Transmitted herewith for this application is/are:
  - a. This Transmittal (3 pages in duplicate);
  - b. Response to Restriction Requirement and Preliminary Amendment (6 pages); and
  - c. Return postcard.

### **STATUS**

2. Applicant is other than a small entity.

	CERTIFICATION UND	ER 37 C.F.R.	SECTIONS 1.8(a) and 1.10*		
I hereby	certify that, on the date shown below, this corre	spondence is	being:		
•		MAILING			
deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commission					
	Patents, P.O. Box 1450, Alexandria, VA 2231	3-1450.	•		
	37 C.F.R. SECTION 1.8(a)		37 C.F.R. SECTION 1.10*		
×	with sufficient postage as first class mail.		as "Express Mail Post Office to Addressee" Mailing Label No.		
	T	<b>TRANSMISS</b>	ION .		
	transmitted by facsimile to the Patent and Trad	lemark Office	Sandy		
			Signature		
Date: M	arch 2, 2006		Sean Hunziker		
			(type or print name of person certifying)		

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 3)

03/07/2006 LWONDIM1 00000058 501668 10786501

## Practitioner's Docket No. MPI98-052P1RDV10DV1M

## PETITION FOR EXTENSION OF TIME

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a one month extension:

Fee:

\$120.00

Extension fee due with this request

\$120.00

\$0.00

If an additional extension of time is required, please consider this a petition therefor.

## FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)	OTHER TH SMALL EN		
	Claims Remaining Aft Amendment		Highest No. Previously Paid For		Present Extra	Rate		Addit. Fee
Total	16	Minus	22	=	0	\$50.00	=	\$0.00
Indep.	2	Minus	2	=	0	\$200.00	=	\$0.00
Multiple Dependent Claims	no		no			\$360.00	=	\$0.00
Ciuilis						Total Addit. Fee		\$0.00

Total additional fee for claims required

## **FEE PAYMENT**

5. Charge Account No. 501668 the sum of \$120.00 (which includes the extension fee). A duplicate of this transmittal is attached.

## Practitioner's Docket No. MPI98-052P1RDV10DV1M

## FEE DEFICIENCY

- 6. If any additional extension and/or fee is required, charge Account No. 501668. If any additional fee for claims is required, charge Account No. 501668.
- 7. Correspondence Address
  Direct all future correspondence to:

Customer Number 30405
OR
Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street

Cambridge, MA 02139

March 2, 2006

MILLENNIUM PHARMACEUTICALS, INC.

Mario Cloutier


Registration No. 57,225

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-577-3522

Facsimile - 617-551-8820



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Susan L. Acton			
Application No.:	10/786,501	Group No.:	1653	
Filed:	February 25, 2004	Examiner:	Maryam Montshipouri	
For:	NOVEL PROTEIN KINASE MOLECULES AND USES THEREFOR			

## Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

Dear Sir:

Responsive to the Restriction Requirement dated January 4, 2006, the claims of Group III (claims 38-41), drawn to antibodies which bind said kinases and methods of use of said antibodies, are elected for prosecution without traverse. In order to be fully responsive, Applicants additionally elect to pursue molecule CSAPK-3 (SEQ ID NO:8).

Applicants hereby reserve the right to traverse the above restriction with respect to nonelected Groups I-II and IV-VI in this or subsequent applications.

### CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

#### MAILING

_	-	MAILING		
×	deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commiss			
	Patents, P.O. Box 1450, Alexandria, VA 22313-1	450.		
	37 C.F.R. SECTION 1.8(a)		37 C.F.R. SECTION 1.10*	
×	with sufficient postage as first class mail.		as "Express Mail Post Office to Addressee"	
			Mailing Label No	
	TRA	NSMISSION _	· 11	
	TRA transmitted by facsimile to the Patent and Tradem	ark Office.	complete	
		Signati	ure	

Date: March 2, 2006 Sean Hunziker

(type or print name of person certifying)

\*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.